stars 1 stars 2 stars 3

At AARDEX Group, we believe in the power of digital solutions to revolutionize the way we measure and manage medication adherence. We're not just talking the talk; we're walking the walk as the world leader in this space. Our cutting-edge technology, MEMS® Adherence Software (MEMS AS®), is the cornerstone of a comprehensive ecosystem designed to deliver accurate, data-driven adherence analytics across all forms of drug administration. But we don't stop there. Our team is dedicated to continuously innovating and pushing the boundaries of what's possible in the world of clinical trials. Our mission is simple yet ambitious: to empower patients and revolutionize the way we approach medication adherence in clinical trials through the use of data and technology. At AARDEX, we're not just making a difference; we're leading the charge.

AARDEX Group - Medication Adherence Tools Questions

The AARDEX Group - Medication Adherence Tools annual revenue was $6.1 million in 2026.

Bernard Vrijens is the Chief Executive Officer and Scientific Lead of AARDEX Group - Medication Adherence Tools.

18 people are employed at AARDEX Group - Medication Adherence Tools.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users